LENSAR, Inc. (LNSR) Tops Q3 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 dips after Trump says Iran deal is 'over'
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022 7:00 AM ESTCompany Launches ALLY Adaptive Cataract Treatment System
Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021
ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2022 and provided a business update.
The third quarter was highlighted by the successful U.S. launch of the ALLY System during the week of August 15th, a pivotal corporate... More
